Additional information
Specialty | |
---|---|
Dosage | |
Form | |
Presentation | |
Primary packaging | |
Specification | |
DCI | |
Classement VEIC | |
Therapeutic class | |
Sub Class | |
Laboratory | |
CHART | |
The duration of the conversation | |
Generic / Princeps | |
AMM | |
Date AMM | |
Range |
Treatment of hypercholesterolemia Adults, adolescents, and children aged 6 years or over with pure hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) in addition to a diet when the response to diet and other non-pharmacological treatments (exercise, weight loss) is not enough. Homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid-lowering treatments (including LDL apheresis) or when these treatments are not appropriate. Prevention of cardiovascular events Prevention of major cardiovascular events in patients considered to be at high risk of having a first cardiovascular event, in addition to the correction of other risk factors.
Specialty | |
---|---|
Dosage | |
Form | |
Presentation | |
Primary packaging | |
Specification | |
DCI | |
Classement VEIC | |
Therapeutic class | |
Sub Class | |
Laboratory | |
CHART | |
The duration of the conversation | |
Generic / Princeps | |
AMM | |
Date AMM | |
Range |